Chagas disease, an infectious illness, poses a grave threat to human health. Our company is committed to developing state-of-the-art antigen, antibody, nucleic acid detection reagents/kits, and auxiliary diagnostic equipment to tackle the complexities in diagnosing Chagas disease.
Introduction to Chagas Disease
Chagas disease, alternatively called American trypanosomiasis, is a disregarded tropical ailment that predominantly impacts people in Latin America. Chagas disease results from the Trypanosoma cruzi parasite, which is transmitted to humans through the feces of triatomine bugs. These insects, nicknamed kissing bugs, deposit the parasite near the bite site, leading to tissue invasion, particularly in the heart muscle, causing chronic inflammation and serious complications like cardiomyopathy.
Fig. 1 Schematic diagram of the transmission of Trypanosoma cruzi. (Duarte-Silva E, et al., 2020)
Diagnostic Biomarkers for Chagas Disease
Due to the diverse clinical manifestations and various stages of infection in Chagas disease, diagnosis can be challenging. Diagnostic biomarkers play a crucial role in accurately detecting the disease, aiding in timely interventions and management. Currently, a variety of biomarkers have been discovered and utilized for the diagnosis of Chagas disease.
Antigens
Various specific antigens of Trypanosoma cruzi, such as TcF, TSSA, B13, and Tc-17, can serve as biomarkers for Chagas disease diagnosis. Immunoassays and lateral flow assays can be employed for antigen detection, offering advantages in sensitivity, specificity, and potential point-of-care applications.
Antibodies
Specific antibodies against Trypanosoma cruzi antigens indicate infection with Chagas disease. Antibody detection for Chagas disease is commonly performed using serological tests like enzyme-linked immunosorbent assay (ELISA) or indirect immunofluorescence assay (IFA).
Trypanosoma Cruzi DNA
Trypanosoma cruzi DNA is an important diagnostic biomarker for detecting and monitoring Chagas disease. Molecular detection techniques such as PCR and LAMP are commonly used to identify the presence of Trypanosoma cruzi DNA in blood samples.
IVD Kits for Chagas Disease
In vitro diagnostic (IVD) kits are crucial for diagnosing, screening, and monitoring individuals infected with Trypanosoma cruzi. At present, a variety of Chagas disease diagnostic kits are commercially available, commonly employing serological testing for antibody detection or molecular testing for parasite DNA detection to diagnose Chagas disease.
| Kits |
Applications |
Detection Methods |
| Chagas PCR Kit |
Qualitative detection of Trypanosoma cruzi specific DNA. |
Real-time PCR (RT-PCR) |
| Chagas Antibody Detection Kit |
Qualitative determination of Trypanosoma cruzi antibodies in serum/plasma samples. |
Electrochemiluminescence Immunoassay (ECLIA) |
| Chagas Antibody Rapid Test Kit |
Qualitative detection of IgG anti-Trypanosoma cruzi in serum, plasma or whole blood. |
Lateral Flow Chromatographic Immunoassay |
Our Services
Through in-depth research into the pathogenesis and metabolic pathways of Chagas disease, our company is dedicated to developing innovative IVD solutions to accurately identify and effectively manage this infectious disease. Our services include the development of antigen, antibody, nucleic acid detection kits, and auxiliary diagnostic equipment. Our goal is to revolutionize Chagas disease diagnosis by creating cutting-edge IVD products.
IVD Product Development Services
Optional IVD Products
- Trypanosoma Cruzi DNA Detection Kit
- Trypanosoma Cruzi Antigen Detection Kit
- Trypanosoma Cruzi Antibody Detection Kit
- Primers and Probes
- DNA Extraction and PCR Reagents
- And More
We offer more than just this. In order to accelerate timely diagnosis and personalized therapies for Chagas disease, we offer point-of-care testing (POCT) and companion diagnostic development services. These services are essential in improving the effectiveness and precision of Chagas disease diagnostics, facilitating tailored care strategies for individuals affected by the disease.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Duarte-Silva E, Morais L H, Clarke G, et al. Targeting the gut microbiota in Chagas disease: what do we know so far?[J]. Frontiers in Microbiology, 2020, 11: 585857.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
